CDR-Life Announces Fourth Milestone Achievement with Boehringer Ingelheim in Phase 1 Geographic Atrophy Trial
April 30, 2024 05:00 ET
|
CDR-Life AG
CDR-Life today announced the advancement of the Phase 1 study with BI 771716, its therapeutic candidate in partnership with Boehringer Ingelheim.
CDR-Life to Present Tumor Targeting Capabilities of M-gager® Platform at the TCR-Based Therapies for Solid Tumors Summit
April 23, 2024 05:00 ET
|
CDR-Life AG
CDR-Life Inc. today announced a presentation at the TCR-Based Therapies for Solid Tumors Summit, occurring April 23-25 in Boston, Massachusetts.
CDR-Life Unveils Results on T-Cell Engagers Targeting Hard-to-Treat Solid Tumors at AACR 2024
April 05, 2024 15:00 ET
|
CDR-Life AG
CDR-Life today announced the presentation of results on T-cell engagers targeting hard-to-treat solid tumors at the AACR Annual Meeting 2024.
CDR-Life Announces FDA Clearance of IND Application for CDR404 for Treatment of Solid Tumors
January 23, 2024 05:00 ET
|
CDR-Life AG
ZURICH, Switzerland, Jan. 23, 2024 (GLOBE NEWSWIRE) -- CDR-Life Inc. today announced the clearance of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA)...
CDR-Life Announces First Patient Dosed in Phase 1 Study with Boehringer Ingelheim Evaluating Potential Treatment for Geographic Atrophy
December 06, 2023 05:00 ET
|
CDR-Life AG
ZÜRICH, Switzerland, Dec. 06, 2023 (GLOBE NEWSWIRE) -- CDR-Life Inc. today announced that the first patient has been dosed in the Phase 1 trial of BI 771716 for the treatment of geographic...
CDR-Life Presents Findings from Two Studies in Preparation of Phase 1 Trial with Immunotherapy CDR404 for Treatment of Solid Tumors at SITC 2023
November 03, 2023 12:00 ET
|
CDR-Life AG
Therapeutic potential of CDR404, as a first-of-its-kind precision immunotherapy for HLA-A*02:01+ patients with MAGE-A4+ squamous non-small cell lung carcinoma (SQ-NSCLC) Development of a Quantitative...
CDR-Life Presents Precise Tumor and Patient Selection for CDR404: First-of-its-Kind Dual MAGE-A4 T-cell Engager, at ESMO Congress 2023
October 23, 2023 05:00 ET
|
CDR-Life AG
- CDR404 represents a potential paradigm shift in the development of T-cell engagers for solid cancers - Epithelial cancer indications eligible for CDR404 Phase 1 trial include non-small cell...
CDR-Life Announces Second Milestone Achievement with Boehringer Ingelheim in Developing Antibody Fragment-based Therapeutics for Geographic Atrophy
August 02, 2023 05:00 ET
|
CDR-Life AG
ZÜRICH, Switzerland, Aug. 02, 2023 (GLOBE NEWSWIRE) -- CDR-Life Inc. today announced a milestone payment triggered by the achievement of a development milestone with a partnered antibody...
CDR-Life Announces the Appointment of Nicole Onetto, MD, MSc, to Board of Directors
December 08, 2022 06:00 ET
|
CDR-Life AG
ZÜRICH, Switzerland, Dec. 08, 2022 (GLOBE NEWSWIRE) -- CDR-Life Inc., a biotechnology company pioneering a new and differentiated class of highly tumor-selective immuno-oncology therapeutics...
CDR-Life to Participate in the 2022 Jefferies London Healthcare Conference
November 01, 2022 07:00 ET
|
CDR-Life AG
ZÜRICH, Switzerland, Nov. 01, 2022 (GLOBE NEWSWIRE) -- CDR-Life Inc., a biotechnology company pioneering a new and differentiated class of highly tumor-selective immuno-oncology therapeutics...